Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

If everyone eligible had a lung cancer screening, 62,000 lives would be saved over five years, a new study shows.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...

Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...